<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02589067</url>
  </required_header>
  <id_info>
    <org_study_id>30529</org_study_id>
    <nct_id>NCT02589067</nct_id>
  </id_info>
  <brief_title>Decolonization of the Oropharynx, an Important and Neglected Reservoir of S. Aureus Colonization</brief_title>
  <official_title>Decolonization of the Oropharynx, an Important and Neglected Reservoir of S. Aureus Colonization.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Thrasher Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The problem of interest is the high rate of recurrent SSTIs in children caused by S. aureus&#xD;
      despite the use of systemic antibiotic treatment, due to difficulties in decolonization and&#xD;
      the prevalence of antibiotic-resistant strains such as MRSA.&#xD;
&#xD;
      This problem will be studied through a randomized, double-blind, placebo-controlled clinical&#xD;
      trial of the use of a 0.12% clorhexidine gluconate (CHG) oral rinse in decolonizing S. aureus&#xD;
      in the oropharynx in children 5-17 years old. CHG is an excellent candidate for use in&#xD;
      children as its safety has been widely established, and it is readily commercially available.&#xD;
      Eligible, consented subjects will be asked to participate in a baseline study visit in which&#xD;
      swabs of their oropharynx and nares are obtained, and they are educated on the use of either&#xD;
      CHG oral rinse or a placebo oral rinse containing saline. The subjects will be instructed to&#xD;
      perform the oral rinse twice daily for seven days. Two follow-up visits will occur at 7 and&#xD;
      28 days post-baseline, where subjects' nares and oropharynx are again swabbed in order to&#xD;
      ascertain short- and long-term decolonization of S. aureus. This procedure will serve to 1)&#xD;
      determine the efficacy of a CHG oral rinse in decolonization of S. aureus, 2) investigate the&#xD;
      safety, tolerability, and compliance of oropharyngeal decolonization among children and their&#xD;
      caregivers, and 3) determine the genetic backgrounds of strains of S. aureus associated with&#xD;
      continued colonization.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each year, children visit doctors offices and emergency rooms over 2 million times due to&#xD;
      skin and soft tissue infections (SSTIs). These SSTIs are usually caused by a bacteria called&#xD;
      Staphylococcus aureus (S. aureus), and can result in severe negative consequences such as&#xD;
      hospitalization, disability, and even death. Despite treatment with antibiotics, 20-70% of&#xD;
      children with an SSTI will develop a recurrent infection within the next year. Additionally,&#xD;
      this treatment fails to eradicate S. aureus from children nearly 50% of the time. Of the&#xD;
      types of S. aureus that cause these infections, antibiotic-resistant strains such as&#xD;
      methicillin-resistant S. aureus (MRSA), which are associated with higher rates of&#xD;
      transmission, have become increasingly more common. Thus, the problem of interest is the high&#xD;
      rate of recurrent SSTIs in children caused by S. aureus despite the use of systemic&#xD;
      antibiotic treatment, due to difficulties in decolonization and the prevalence of&#xD;
      antibiotic-resistant strains such as MRSA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Eradiction of S. Aureus From the Oropharyngeal at 7 Days</measure>
    <time_frame>7 days</time_frame>
    <description>The primary endpoint is eradication of S. aureus oropharyngeal colonization at 7 days using an intention to treat (ITT) model.&#xD;
.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Eradication of S. Aureus Oropharyngeal Colonization at 28 Days</measure>
    <time_frame>28 days</time_frame>
    <description>Secondary outcome is eradication of S. aureus oropharyngeal colonization at 28 days using an intention to treat (ITT) model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Persistent Same Strain of S. Aureus Genetic Backgrounds at 28 Days</measure>
    <time_frame>28 days</time_frame>
    <description>We characterized isolates associated with breakthrough of oropharyngeal colonization. Here we show the breakthrough isolates of the same strain at 28 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Persistent Different Strain of S. Aureus Genetic Backgrounds at 28 Days</measure>
    <time_frame>28 days</time_frame>
    <description>We characterized isolates associated with breakthrough of oropharyngeal colonization. Here we show the breakthrough isolates of different strains at 28 days.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>S. Aureus Oropharyngeal Colonization</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized to 15mL 0.12% Chlorhexidine Gluconate oral rinse, to be used twice daily for 60 seconds for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Randomized to 15mL saline placebo oral rinse, to be used twice daily for 60 seconds for 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorhexidine gluconate</intervention_name>
    <description>Oral rinse of either 0.12% Chlorhexidine Gluconate oral rinse to test the safety/efficacy of 0.12% Chlorhexidine Gluconate oral rinse in decolonizing the oropharynx of children colonized with S. aureus.</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Peridex</other_name>
    <other_name>Periogard</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline Placebo</intervention_name>
    <description>Placebo saline oral rinse to to test the safety/efficacy of 0.12% Chlorhexidine Gluconate oral rinse in decolonizing the oropharynx of children colonized with S. aureus.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. History of skin or soft tissue infection that occurred between 1 month and 5 years&#xD;
             ago, regardless of whether antibiotics were given, as per patient report&#xD;
&#xD;
          2. Age &gt; 5 years and &lt; 18 years.&#xD;
&#xD;
          3. Able to gargle as assessed by verbal question.&#xD;
&#xD;
          4. Willing and able to undergo nares and oropharyngeal swabbing.&#xD;
&#xD;
          5. Able to come to the research clinic for study follow-up visits for the study period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current suspected or confirmed infection requiring systemic antibiotics.&#xD;
&#xD;
          2. Receipt of systemic antibiotics in the prior 28 days.&#xD;
&#xD;
          3. Plans for administration or likely receipt of systemic antibiotics in the next 28 days&#xD;
             (e.g., if the patient suffers from recurrent infections such as otitis media or has a&#xD;
             planned surgery that requires prophylactic antibiotics).&#xD;
&#xD;
          4. Plans for hospitalization or likely hospitalization in the next 28 days (e.g., if the&#xD;
             patient suffers from recurrent infections)&#xD;
&#xD;
          5. Any of the following in the prior 6 months: hemodialysis, peritoneal dialysis, central&#xD;
             venous catheter placement, and systemic chemotherapy for cancer, any&#xD;
             immune-compromising condition.&#xD;
&#xD;
          6. Previous participation in the study.&#xD;
&#xD;
          7. Pregnancy (all female subjects of childbearing age will be given a pregnancy test&#xD;
             prior to enrollment).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Loren G Miller, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Los Angeles BioMedical Research Institute (LA BioMed)</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 20, 2015</study_first_submitted>
  <study_first_submitted_qc>October 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2015</study_first_posted>
  <results_first_submitted>June 15, 2020</results_first_submitted>
  <results_first_submitted_qc>December 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 29, 2020</results_first_posted>
  <last_update_submitted>December 3, 2020</last_update_submitted>
  <last_update_submitted_qc>December 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorhexidine</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After publication of trial results, data will be shared with investigators upon request to the Principal Investigator and after signing a Data Use Agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 30, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT02589067/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>0.12% Chlorhexidine Gluconate Oral Rinse</title>
          <description>Randomized to 15mL 0.12% Chlorhexidine Gluconate oral rinse, to be used twice daily for 60 seconds for 7 days.&#xD;
Chlorhexidine gluconate: Oral rinse of either 0.12% Chlorhexidine Gluconate oral rinse to test the safety/efficacy of 0.12% Chlorhexidine Gluconate oral rinse in decolonizing the oropharynx of children colonized with S. aureus.</description>
        </group>
        <group group_id="P2">
          <title>Saline Placebo Oral Rinse</title>
          <description>Randomized to 15mL saline placebo oral rinse, to be used twice daily for 60 seconds for 7 days.&#xD;
Saline Placebo: Placebo saline oral rinse to to test the safety/efficacy of 0.12% Chlorhexidine Gluconate oral rinse in decolonizing the oropharynx of children colonized with S. aureus.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>0.12% Chlorhexidine Gluconate Oral Rinse</title>
          <description>Randomized to 15mL 0.12% Chlorhexidine Gluconate oral rinse, to be used twice daily for 60 seconds for 7 days.&#xD;
Chlorhexidine gluconate: Oral rinse of either 0.12% Chlorhexidine Gluconate oral rinse to test the safety/efficacy of 0.12% Chlorhexidine Gluconate oral rinse in decolonizing the oropharynx of children colonized with S. aureus.</description>
        </group>
        <group group_id="B2">
          <title>Saline Placebo Oral Rinse</title>
          <description>Randomized to 15mL saline placebo oral rinse, to be used twice daily for 60 seconds for 7 days.&#xD;
Saline Placebo: Placebo saline oral rinse to to test the safety/efficacy of 0.12% Chlorhexidine Gluconate oral rinse in decolonizing the oropharynx of children colonized with S. aureus.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="34"/>
            <count group_id="B3" value="67"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11" spread="11.7"/>
                    <measurement group_id="B2" value="12.4" spread="11.7"/>
                    <measurement group_id="B3" value="11" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>White Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White Not Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian/Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black/African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Eradiction of S. Aureus From the Oropharyngeal at 7 Days</title>
        <description>The primary endpoint is eradication of S. aureus oropharyngeal colonization at 7 days using an intention to treat (ITT) model.&#xD;
.</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.12% Chlorhexidine Gluconate Oral Rinse</title>
            <description>Randomized to 15mL 0.12% Chlorhexidine Gluconate oral rinse, to be used twice daily for 60 seconds for 7 days.&#xD;
Chlorhexidine gluconate: Oral rinse of either 0.12% Chlorhexidine Gluconate oral rinse to test the safety/efficacy of 0.12% Chlorhexidine Gluconate oral rinse in decolonizing the oropharynx of children colonized with S. aureus.</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo Oral Rinse</title>
            <description>Randomized to 15mL saline placebo oral rinse, to be used twice daily for 60 seconds for 7 days.&#xD;
Saline Placebo: Placebo saline oral rinse to to test the safety/efficacy of 0.12% Chlorhexidine Gluconate oral rinse in decolonizing the oropharynx of children colonized with S. aureus.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Eradiction of S. Aureus From the Oropharyngeal at 7 Days</title>
          <description>The primary endpoint is eradication of S. aureus oropharyngeal colonization at 7 days using an intention to treat (ITT) model.&#xD;
.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Eradication of S. Aureus Oropharyngeal Colonization at 28 Days</title>
        <description>Secondary outcome is eradication of S. aureus oropharyngeal colonization at 28 days using an intention to treat (ITT) model.</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.12% Chlorhexidine Gluconate Oral Rinse</title>
            <description>Randomized to 15mL 0.12% Chlorhexidine Gluconate oral rinse, to be used twice daily for 60 seconds for 7 days.&#xD;
Chlorhexidine gluconate: Oral rinse of either 0.12% Chlorhexidine Gluconate oral rinse to test the safety/efficacy of 0.12% Chlorhexidine Gluconate oral rinse in decolonizing the oropharynx of children colonized with S. aureus.</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo Oral Rinse</title>
            <description>Randomized to 15mL saline placebo oral rinse, to be used twice daily for 60 seconds for 7 days.&#xD;
Saline Placebo: Placebo saline oral rinse to to test the safety/efficacy of 0.12% Chlorhexidine Gluconate oral rinse in decolonizing the oropharynx of children colonized with S. aureus.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Eradication of S. Aureus Oropharyngeal Colonization at 28 Days</title>
          <description>Secondary outcome is eradication of S. aureus oropharyngeal colonization at 28 days using an intention to treat (ITT) model.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Persistent Same Strain of S. Aureus Genetic Backgrounds at 28 Days</title>
        <description>We characterized isolates associated with breakthrough of oropharyngeal colonization. Here we show the breakthrough isolates of the same strain at 28 days.</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.12% Chlorhexidine Gluconate Oral Rinse</title>
            <description>Randomized to 15mL 0.12% Chlorhexidine Gluconate oral rinse, to be used twice daily for 60 seconds for 7 days.&#xD;
Chlorhexidine gluconate: Oral rinse of either 0.12% Chlorhexidine Gluconate oral rinse to test the safety/efficacy of 0.12% Chlorhexidine Gluconate oral rinse in decolonizing the oropharynx of children colonized with S. aureus.</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo Oral Rinse,</title>
            <description>Randomized to 15mL saline placebo oral rinse, to be used twice daily for 60 seconds for 7 days.&#xD;
Saline Placebo: Placebo saline oral rinse to to test the safety/efficacy of 0.12% Chlorhexidine Gluconate oral rinse in decolonizing the oropharynx of children colonized with S. aureus.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Persistent Same Strain of S. Aureus Genetic Backgrounds at 28 Days</title>
          <description>We characterized isolates associated with breakthrough of oropharyngeal colonization. Here we show the breakthrough isolates of the same strain at 28 days.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Persistent Different Strain of S. Aureus Genetic Backgrounds at 28 Days</title>
        <description>We characterized isolates associated with breakthrough of oropharyngeal colonization. Here we show the breakthrough isolates of different strains at 28 days.</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.12% Chlorhexidine Gluconate Oral Rinse</title>
            <description>Randomized to 15mL 0.12% Chlorhexidine Gluconate oral rinse, to be used twice daily for 60 seconds for 7 days.&#xD;
Chlorhexidine gluconate: Oral rinse of either 0.12% Chlorhexidine Gluconate oral rinse to test the safety/efficacy of 0.12% Chlorhexidine Gluconate oral rinse in decolonizing the oropharynx of children colonized with S. aureus.</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo Oral Rinse,</title>
            <description>Randomized to 15mL saline placebo oral rinse, to be used twice daily for 60 seconds for 7 days.&#xD;
Saline Placebo: Placebo saline oral rinse to to test the safety/efficacy of 0.12% Chlorhexidine Gluconate oral rinse in decolonizing the oropharynx of children colonized with S. aureus.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Persistent Different Strain of S. Aureus Genetic Backgrounds at 28 Days</title>
          <description>We characterized isolates associated with breakthrough of oropharyngeal colonization. Here we show the breakthrough isolates of different strains at 28 days.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>0.12% Chlorhexidine Gluconate Oral Rinse</title>
          <description>Randomized to 15mL 0.12% Chlorhexidine Gluconate oral rinse, to be used twice daily for 60 seconds for 7 days.&#xD;
Chlorhexidine gluconate: Oral rinse of either 0.12% Chlorhexidine Gluconate oral rinse to test the safety/efficacy of 0.12% Chlorhexidine Gluconate oral rinse in decolonizing the oropharynx of children colonized with S. aureus.</description>
        </group>
        <group group_id="E2">
          <title>Saline Placebo Oral Rinse</title>
          <description>Randomized to 15mL saline placebo oral rinse, to be used twice daily for 60 seconds for 7 days.&#xD;
Saline Placebo: Placebo saline oral rinse to to test the safety/efficacy of 0.12% Chlorhexidine Gluconate oral rinse in decolonizing the oropharynx of children colonized with S. aureus.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>other</sub_title>
                <description>Patient experienced vomiting</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Loren G. Miller</name_or_title>
      <organization>The Lundquist Institute at Harbor-UCLA</organization>
      <phone>310-222-3775</phone>
      <email>lmiller@lundquist.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

